U.S., March 22 -- ClinicalTrials.gov registry received information related to the study (NCT06888310) titled 'Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease' on July 11, 2024.
Brief Summary: Non-alcoholic fatty liver disease (NAFLD) is responsible for a significant proportion of liver-related deaths and healthcare costs in the United States, accounting for approximately 36% of liver-related deaths and over one billion dollars in annual healthcare expenses. [PMID: 34863359] A recent analysis of healthcare costs in Italy showed that out of the 9,729 NAFLD/NASH patients who were hospitalized and analyzed, the vast majority (97%) did not have advanced liver disease, while 1.3% had compensated advanced live...